News | July 11, 2025
Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
The pharmaceuticals laboratory supports North Asia with formulation development, reverse engineering, troubleshooting, and analysis for various dosage forms
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
The Stryker Mako Robotic System uses artificial intelligence to improve surgical accuracy with real-time guidance, personalized planning, and precise execution
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
He has held senior leadership positions at Syngene International, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific, Sartorius Stedim Biotech, and other leading organizations
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Subscribe To Our Newsletter & Stay Updated
